12:00 AM
 | 
Jan 22, 2002
 |  BioCentury  |  Product Development

PEG-Intron: Supply & demand

Aligning supply with demand is a fundamental tenet in business. Schering-Plough Corp. anticipated that demand would be high for its PEG-Intron pegylated interferon alpha-2b, which was approved last year to treat hepatitis C, because of its more convenient dosing compared to conventional interferon. Even so, the company under-estimated its requirements to supply the product, which is formulated using PEG technology from Enzon Inc. (ENZN, Piscataway, N.J.).

While there's a chance SGP now may lose some patients who will instead use conventional interferon, the company thinks it more likely that most will be able...

Read the full 447 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >